We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome

This study is currently recruiting participants.
Verified November 2017 by Alexander A Ostanin, Russian Academy of Medical Sciences
Sponsor:
ClinicalTrials.gov Identifier:
NCT02957123
First Posted: November 7, 2016
Last Update Posted: November 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Alexander A Ostanin, Russian Academy of Medical Sciences
  Purpose
The investigators have designed an innovative proof-of-concept trial designed to provide data as to whether the treatment/rehabilitation efficacy and functional outcome of patients with organic brain syndrome are improved with intranasal inhalations of bioactive factors (BF), produced by autologous M2 macrophages (auto-M2-BFs). The rationale for this approach is the ability of central nervous system to repair and the important role of macrophages in the regulation of this process. It was found that type 2 macrophages have anti-inflammatory and reparative potential, whereas M1 cells possess pro-inflammatory and neurotoxic effects. Action of M2 macrophages is largely realized through the production a wide variety of bioactive factors (cytokines, chemokines, growth factors, neuropeptides, microvesicles etc) that inhibit inflammation, protect neurons from apoptosis, stimulate neurogenesis, the growth and remyelination of axons, the formation of new synapses and activate angiogenesis. This study uses auto-M2-BFs, as therapeutic agents and intranasal administration focusing on nose to brain transport, as a mode of delivery. Expected clinical effects in treated subjects: improvement of cognitive functions (memory, language, attention); correction of focal neurological deficit (paresis, spasticity, sensory disorders); reduction vestibular/ataxic disorders (vertigo, unsteadiness when walking); reduction of headaches; reduction of asthenia (weakness, fatigue); correction of emotional disorders (anxiety, depression).

Condition Intervention Phase
Organic Brain Syndrome, Nonpsychotic Neurocognitive Disorders Mental Disorder, Organic Delirium, Dementia, Amnestic, Cognitive Disorders Nonpsychotic Organic Brain Syndrome Organic Mental Disorder Encephalopathy, Post-Traumatic, Chronic Encephalopathy, Ischemic Brain Ischemia Drug: Intranasal auto-M2-BFs Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety/Efficacy of Intranasally-Administered Bioactive Factors Produced by Autologous M2 Macrophages in Patients With Organic Brain Syndrome

Further study details as provided by Alexander A Ostanin, Russian Academy of Medical Sciences:

Primary Outcome Measures:
  • The number of patients with adverse events [ Time Frame: up to 6 months after treatment ]
    Occurrence of adverse events including allergic, toxic, inflammatory reactions; neurological worsening; seizures


Secondary Outcome Measures:
  • Change in neurological status [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in National Institutes of Health Stroke Scale (NIHSS) for post-stroke patients [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in Barthel ADL index [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in Instrumental Activities of Daily Living (IADL) scale [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in Basic Activities of Daily Living scale [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in Hospital Anxiety and Depression scale (HAD) [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in Modified Ashworth Scale of Muscle Spasticity [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in Montreal Cognitive Assessment (МоСА) [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]
  • Change in Performance Oriented Mobility Assessment (POMA) [ Time Frame: Baseline, 4 weeks and 6 months after treatment ]

Estimated Enrollment: 60
Actual Study Start Date: March 2016
Estimated Study Completion Date: May 2021
Estimated Primary Completion Date: November 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intranasal auto-M2-BFs

Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.

60 patients with organic brain syndrome will receive their first doses (n=2-3) of auto-M2-BFs in clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose.

The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment.

Drug: Intranasal auto-M2-BFs
Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
Other Name: Bioactive Factors, Produced by M2 Macrophage

Detailed Description:

Following injury to the central nervous system (CNS), immune-mediated inflammation profoundly affects the ability of neural cells to survive and to regenerate. The role of inflammation comprises mostly of macrophages, is controversial, since macrophages can both induce neuronal and glial toxicity and promote tissue repair. The opposite effects of macrophages may be conditioned by their functional heterogeneity. Thus, classical pro-inflammatory macrophages (M1) are tissue-destructive, while anti-inflammatory (M2) macrophages mediate tissue repair. In addition, M2 macrophages predominantly induce the Th2 response, which is particularly beneficial in CNS repair. Using low serum conditions the investigators have generated M2-like macrophages and evaluated their phenotypic and functional features [1, 2]. Our data indicate that M2 macrophages, in contrast to pro-inflammatory M1 cells, produced significantly lower levels of pro-inflammatory cytokines (IL-1β, tumor necrosis factor-α, IL-6, IL-18, IL-12), chemokines (IL-8, monocyte chemoattractant protein 1-1) and Th1/Th2-cytokines (interferon-γ, IL-2, IL-4) coupled with a higher IL-10 level. M2 macrophages were capable of producing neurotrophic- (brain-derived neurotrophic factor,insulin-like growth factor-1), angiogenic- (vascular endothelial growth factor), and other growth factors (erythropoietin, granulocyte-colony stimulating factor , basic fibroblast growth factor, epidermal growth factor) with neuroprotective and regenerative activity.

Our pilot clinical trials have demonstrated the safety and clinical efficacy of intrathecal administration of M2 macrophages in children with severe cerebral palsy [3] and in non-acute stroke patients [4].

Since cell-free culture medium of M2 macrophages contains a wide variety of neurotrophic, immunoregulatory and pro-angiogenic factors, the investigators expect that intranasal administration of these auto-M2-BFs will improve the treatment/rehabilitation efficacy and functional outcome of patients with organic brain syndrome. Of note, intranasal administration of M2-macrophage soluble factors allow to delivery bioactive agents to brain through the olfactory and trigeminal ways across brain-blood barrier.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults: age 18 - 80
  • Persistent neurological deficits (cognitive, mental, motor, vestibular/ataxic disorders as a result of trauma, cardiovascular, neurodegenerative and others cerebral injuries), confirmed clinically and by CT or MRI
  • A written informed consent of the patient or close relatives

Exclusion Criteria:

  • Psychiatric disorders
  • Seizures
  • Severe dementia
  • Hepatic or renal dysfunctions
  • Hemodynamic or respiratory instability
  • HIV or uncontrolled bacterial, fungal, or viral infections
  • Pregnancy
  • Malignancy
  • Intolerance to gentamicin and / or multiple drug allergies
  • Participation in other clinical trials
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02957123


Contacts
Contact: Natalia M Starostina, PhD +7 (383) 228-27-41 starostina48@bk.ru
Contact: Mariya N Davydova +7 (383) 228-54-21 davydoff2002@mail.ru

Locations
Russian Federation
Institute of Fundamental and Clinical Immunology Recruiting
Novosibirsk, Russian Federation, 630099
Contact: Elena R Chernykh, MD, PhD    +7 (383) 236-03-29    ct_lab@mail.ru   
Contact: Alexander A Ostanin, MD, PhD    +7 (383) 236-03-29    ostanin62@mail.ru   
Sponsors and Collaborators
Russian Academy of Medical Sciences
Investigators
Study Chair: Elena R Chernykh, MD, PhD Institute of Fundamental and Clinical Immunology
Principal Investigator: Alexander A Ostanin, MD, PhD Institute of Fundamental and Clinical Immunology
  More Information

Publications:
Responsible Party: Alexander A Ostanin, Institute of Fundamental and Clinical Immunology, Russian Academy of Medical Sciences
ClinicalTrials.gov Identifier: NCT02957123     History of Changes
Other Study ID Numbers: IFCI-25/05/2015
First Submitted: November 3, 2016
First Posted: November 7, 2016
Last Update Posted: November 8, 2017
Last Verified: November 2017

Keywords provided by Alexander A Ostanin, Russian Academy of Medical Sciences:
macrophages M2 type
cytokines
intranasal administration
neuroprotection
neuroregeneration
organic brain syndrome
neurocognitive disorders

Additional relevant MeSH terms:
Disease
Syndrome
Dementia
Ischemia
Delirium
Brain Diseases
Mental Disorders
Psychotic Disorders
Cognition Disorders
Brain Ischemia
Neurocognitive Disorders
Chronic Traumatic Encephalopathy
Pathologic Processes
Central Nervous System Diseases
Nervous System Diseases
Confusion
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Schizophrenia Spectrum and Other Psychotic Disorders
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Brain Injuries, Traumatic
Brain Injuries
Brain Injury, Chronic
Neurodegenerative Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries